Literature DB >> 33285132

Establishment and Implementation of Evidence-Based Opioid Prescribing Guidelines in Cardiac Surgery.

Alexander A Brescia1, Melissa J Clark2, Patricia F Theurer2, Shelly C Lall3, Hassan W Nemeh4, Richard S Downey5, David E Martin6, Reza R Dabir7, Zewditu E Asfaw8, Phillip L Robinson9, Steven D Harrington10, Divyakant B Gandhi11, Jennifer F Waljee12, Michael J Englesbe13, Chad M Brummett14, Richard L Prager15, Donald S Likosky16, Karen M Kim17, Kiran H Lagisetty18.   

Abstract

BACKGROUND: Despite the risk of new persistent opioid use after cardiac surgery, postdischarge opioid use has not been quantified and evidence-based prescribing guidelines have not been established.
METHODS: Opioid-naive patients undergoing primary cardiac surgery via median sternotomy between January and December 2019 at 10 hospitals participating in a statewide collaborative were selected. Clinical data were linked to patient-reported outcomes collected at 30-day follow-up. An opioid prescribing recommendation stratified by inpatient opioid use on the day before discharge (0, 1-3, or ≥4 pills) was implemented in July 2019. Interrupted time-series analyses were performed for prescription size and postdischarge opioid use before (January to June) and after (July to December) guideline implementation.
RESULTS: Among 1495 patients (729 prerecommendation and 766 postrecommendation), median prescription size decreased from 20 pills to 12 pills after recommendation release (P < .001), while opioid use decreased from 3 pills to 0 pills (P < .001). Change in prescription size over time was +0.6 pill/month before and -0.8 pill/month after the recommendation (difference = -1.4 pills/month; P = .036). Change in patient use was +0.6 pill/month before and -0.4 pill/month after the recommendation (difference = -1.0 pills/month; P = .017). Pain levels during the first week after surgery and refills were unchanged. Patients using 0 pills before discharge (n = 710) were prescribed a median of 0 pills and used 0 pills, while those using 1 to 3 pills (n = 536) were prescribed 20 pills and used 7 pills, and those using greater than or equal to 4 pills (n = 249) were prescribed 32 pills and used 24 pills.
CONCLUSIONS: An opioid prescribing recommendation was effective, and prescribing after cardiac surgery should be guided by inpatient use.
Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33285132      PMCID: PMC8550876          DOI: 10.1016/j.athoracsur.2020.11.015

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   5.102


  27 in total

1.  New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults.

Authors:  Chad M Brummett; Jennifer F Waljee; Jenna Goesling; Stephanie Moser; Paul Lin; Michael J Englesbe; Amy S B Bohnert; Sachin Kheterpal; Brahmajee K Nallamothu
Journal:  JAMA Surg       Date:  2017-06-21       Impact factor: 14.766

2.  An Educational Intervention Decreases Opioid Prescribing After General Surgical Operations.

Authors:  Maureen V Hill; Ryland S Stucke; Michelle L McMahon; Julia L Beeman; Richard J Barth
Journal:  Ann Surg       Date:  2018-03       Impact factor: 12.969

3.  Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures.

Authors:  Maureen V Hill; Michelle L McMahon; Ryland S Stucke; Richard J Barth
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

4.  Results of a Prospective, Multicenter Initiative Aimed at Developing Opioid-prescribing Guidelines After Surgery.

Authors:  Cornelius A Thiels; Daniel S Ubl; Kathleen J Yost; Sean C Dowdy; Tad M Mabry; Halena M Gazelka; Robert R Cima; Elizabeth B Habermann
Journal:  Ann Surg       Date:  2018-09       Impact factor: 12.969

5.  Impact of Prescribing on New Persistent Opioid Use After Cardiothoracic Surgery.

Authors:  Alexander A Brescia; Jennifer F Waljee; Hsou Mei Hu; Michael J Englesbe; Chad M Brummett; Pooja A Lagisetty; Kiran H Lagisetty
Journal:  Ann Thorac Surg       Date:  2019-08-22       Impact factor: 4.330

6.  New Persistent Opioid Use After Aortic and Mitral Valve Surgery in Commercially Insured Patients.

Authors:  Kathleen C Clement; Joseph K Canner; Glenn J R Whitman; Jennifer S Lawton; Michael C Grant; Marc S Sussman
Journal:  Ann Thorac Surg       Date:  2020-01-29       Impact factor: 4.330

7.  The Society of Thoracic Surgeons National Database 2019 Annual Report.

Authors:  Felix G Fernandez; David M Shahian; Robert Kormos; Jeffrey P Jacobs; Richard S D'Agostino; John E Mayer; Benjamin D Kozower; Robert S D Higgins; Vinay Badhwar
Journal:  Ann Thorac Surg       Date:  2019-10-22       Impact factor: 4.330

8.  The REDCap consortium: Building an international community of software platform partners.

Authors:  Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda
Journal:  J Biomed Inform       Date:  2019-05-09       Impact factor: 6.317

9.  Association of Opioid Overdose With Opioid Prescriptions to Family Members.

Authors:  Nazleen F Khan; Brian T Bateman; Joan E Landon; Joshua J Gagne
Journal:  JAMA Intern Med       Date:  2019-09-01       Impact factor: 21.873

10.  Rates and risk factors for prolonged opioid use after major surgery: population based cohort study.

Authors:  Hance Clarke; Neilesh Soneji; Dennis T Ko; Lingsong Yun; Duminda N Wijeysundera
Journal:  BMJ       Date:  2014-02-11
View more
  2 in total

1.  Radiomics Represent a New Opportunity for Bariatric Surgery When Implemented in a Quality Improvement Context.

Authors:  Dimitrios E Magouliotis; Dimitris Zacharoulis
Journal:  Obes Surg       Date:  2022-06-18       Impact factor: 3.479

2.  Perioperative Opioids, the Opioid Crisis, and the Anesthesiologist.

Authors:  Daniel B Larach; Jennifer M Hah; Chad M Brummett
Journal:  Anesthesiology       Date:  2022-04-01       Impact factor: 7.892

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.